Acute liver failure

Current Opinion in Gastroenterology

Volumn 17, Issue 3, 2001, Pages 291-298

  Fontana, Robert J ^a,b   Quallich, Leonard G ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMFENAC; NEFAZODONE; PARACETAMOL; RITONAVIR; TROGLITAZONE; TROVAFLOXACIN;

BRAIN EDEMA; DRUG INDUCED DISEASE; DRUG OVERDOSE; HUMAN; HYPOTHERMIA; INTRACRANIAL PRESSURE; LIVER FAILURE; LIVER TOXICITY; MORBIDITY; MORTALITY; REVIEW; TOXIC HEPATITIS; VIRUS HEPATITIS;

EID: 0035045761     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200105000-00013     Document Type: Review

References (104)

1. Fulminant hepatic failure: A summary of a workshop
2. Acute hepatic failure: A Western perspective
3. Acute hepatic failure in India: A perspective from the East
4. Etiology and outcome from 295 patients with acute liver failure in the United States
5. Etiology and outcome of acute liver failure in the USA: Preliminary results of a prospective multicenter study
6. Fulminant hepatitis A in patients with chronic liver disease
7. Hepatitis B virus infection
8. Recombinant vaccine against hepatitis E: Dose response and protection against heterologous challenge
9. Fulminant non-A-G viral hepatitis leading to liver transplantation
10. A novel DNA virus (TTV) associated with elevated transaminase levels in post transfusion hepatitis of unknown etiology
11. Transfusion associated TT virus infection and its relationship to liver disease
12. The incidence of SEN virus infection in transfusion associated hepatitis
13. The prevalence of SEN virus infection in Japanese patients with viral hepatitis and liver disease
14. Occult HBV infection in acute liver failiure patients in the United States
15. 1994 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System
16. A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993)
17. Paracetamol overdose in a liver transplantation center: An 8-year experience
18. Acetaminophen toxicity in an urban county hospital
19. Outcome of acetaminophen induced liver failure in the USA in suicidal versus accidental overdose: Preliminary results of a prospective, multi-center trial
20. Recognition and management of acetaminophen hepatotoxicity: A comparison of gastroenterologists and primary care physicians
21. Association of acetaminophen hepatotoxicity with fasting and alcohol use
22. From the Food and Drug Administration: New alcohol warning required for OTC analgesic/antipyretic products
23. The safety of newly approved medicine: Do recent market removals mean there is a problem?
24. Limitation of over the counter sales of paracetamol: Packaging policy is unlikely to achieve its aim of reducing suicide
25. Change in occurrence of paracetamol overdose in the UK after the introduction of blister packs
26. Severity of overdose after restriction of paracetamol availability: Retrospective study
27. Hepatic dysfunction associated with troglitazone
28. A novel antidiabetic drug, troglitazone: Reason for hope and concern
29. Troglitazone-associated hepatic failure
30. Rapid-onset subfulminant liver failure associated with troglitazone
31. Troglitazone-induced fulminant hepatic failure, Acute Liver Failure Study Group
32. Troglitazone-induced hepatic failure leading to liver transplantation: A case report
33. Hepatocellular injury in a patient receiving rosiglitazone: A case report
34. Hepatic failure in a patient taking rosiglitazone
35. New warnings issued for bromfenac, astemizole
36. Severe hepatotoxicity associated with bromfenac sodium
37. Fatal fulminant hepatitis associated with bromfenac use
38. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation: The Acute Liver Failure Study Group
39. Methodological and political issues in clinical pharmacologic research by the year 2000
40. Nefazodone-induced liver failure: Report of three cases
41. Reversible nefazadone-induced liver failure
42. Nefazadone-induced acute liver failure
43. Trovafloxacin-induced acute hepatitis
44. From the Food and Drug Administration: Trovofloxacin public health advisory
45. Acute eosinophilic hepatitis from trovofloxacin
46. Comparative tolerability of the newer flouroquinolone antibacterials
47. COX 2 inhibitor and fulminant hepatic failure
48. Celecoxib-induced acute pancreatitis and hepatitis: A case report
49. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
50. Elevated liver enzymes following initiation of antiretroviral therapy
51. Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy
52. Lactic acidosis and hepatic steatosis associated with use of stavudine: Report of four cases
53. Early indicators of prognosis in fulminant hepatic failure
54. Acute liver failure: Clinical features, outcome analysis, and applicability of prognostic criteria
55. Early indicators of prognosis in fulminant hepatic failure: An assessment of the King's criteria
56. Use and validation of selection criteria for liver transplantation in acute liver failure
57. Liver transplantation: Current management, fulminant hepatic failure
58. The systemic inflammatory response syndrome in acute liver failure
59. The management of abnormalities of hemostasis in acute liver failure
60. Recombinant activated factor VII in fulminant liver failure: Complete but transient correction of the coagulopathy
61. Pathophysiology of cerebral edema in fulminant hepatic failure
62. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration
63. Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure
64. Intracranial pressure during liver transplantation for fulminant hepatic failure
65. Subclinical seizure activity and prophylactic phenytoin infusion in acute liver failure: A controlled clinical trial
66. Mild hypothermia delays the onset of coma and prevents brain edema and extracellular brain glutamate accumulation in rats with acute liver failure
67. Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure
68. Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure
69. Current state of liver support systems
70. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure
71. Clinical experience with a bioartificial liver in the treatment of severe liver failure: A phase I clinical trial
72. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled clinical trial
73. Liver support by extracorporeal blood purification: A clinical observation
74. Use of liver transplantation in patients with acute liver failure
75. Liver transplantation in Europe for patients with acute liver failure
76. The American experience with transplantation for acute liver failure
77. Auxiliary versus orthotopic liver transplantation for acute liver failure: EURALT Study Group, European Auxiliary Liver Transplant Registry
78. Liver transplantation from live donors
79. Improved results of living related liver transplantation with routine application in a pediatric program
80. Living donor liver transplantation in adults: Outcome in Japan
81. Donor health assessment following living donor liver transplantation
82. Impact of graft size mismatching on graft prognosis in liver transplantation from living donors
83. Living related liver transplantation in adults
84. Living donor liver transplantation in adults: Outcome in Europe
85. Single center analysis of the first 40 adult-to-adult living donor liver transplants using the right lobe
86. Liver regeneration and function in donor and recipient after right lobe adult to adult living donor liver transplantation
87. Selection of donors and recipients for living donor liver transplantation
88. Living related-donor liver transplantation for adult fulminant hepatic failure
89. Living-related liver transplantation for patients with fulminant and subfulminant hepatic failure
90. Living related liver transplantation for acute liver failure in children
91. Successful living related liver transplantation in an adult with fulminant hepatic failure
92. Emergency adult to adult living donor liver transplantation for fulminant hepatic failure
93. Ethical issues surrounding adult-to-adult living donor liver transplantation
94. Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia
95. Hepatocyte transplantation as a bridge to orthotopic liver transplantation in terminal liver failure
96. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation
97. Hepatocyte transplantation in acute liver failure
98. Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloblastoma
99. Bone marrow as a potential source of hepatic oval cells
100. Liver from bone marrow in humans
101. Safety packaging of acetaminophen combination preparations and severity of adult poisoning
102. Paracetamol self-poisoning: Characteristics, prevention and harm reduction
103. Reduction in incidence of severe paracetamol poisoning
104. Living donor liver transplantation for fulminant hepatic failure